Cost-effectiveness of adalimumab (Humira™) in the treatment of US patients with rheumatoid arthritis (RA)

被引：1
|
作者：
Bansback, N
Brennan, A
Sengupta, N
机构：
[1] Univ Sheffield, Sheffield S10 2TN, S Yorkshire, England
[2] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
VALUE IN HEALTH | 2004年 / 7卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)62129-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：241 / 241
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness treatment with Rituximab in patients with rheumatoid arthritis in real life
    Maurizio Benucci
    Gianantonio Saviola
    Paola Baiardi
    Mariangela Manfredi
    Rheumatology International, 2011, 31 : 1465 - 1469
  • [42] Regional Differences Between Patients With Rheumatoid Arthritis (RA) in Canada at Initiation of Adalimumab Treatment in Canada: Results of the Optimization of Humira Trial
    Haraoui, Boulos
    Pope, Janet
    Thorne, Carter
    Sampalis, John
    Psaradellis, Fotoula
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (11) : 2578 - 2578
  • [43] Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept
    Gholami, Ahmad
    Azizpoor, Jassem
    Aflaki, Elham
    Rezaee, Mehdi
    Keshavarz, Khosro
    BIOMED RESEARCH INTERNATIONAL, 2021, 2021
  • [44] COST-EFFECTIVENESS OF RITUXIMAB (MABTHERA) COMPARED WITH TNF INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN POLAND
    Plisko, R.
    Krzystek, J.
    Rys, P.
    Russel-Szymczyk, M.
    Szkultecka-Debek, M.
    Szamotulska, K.
    VALUE IN HEALTH, 2008, 11 (06) : A544 - A544
  • [45] THE COST-EFFECTIVENESS OF ALTERNATIVE TREATMENT SEQUENCES IN RHEUMATOID ARTHRITIS
    Trueman, D.
    Bird, A.
    Mumby-Croft, J.
    VALUE IN HEALTH, 2014, 17 (03) : A48 - A48
  • [46] COST-EFFECTIVENESS ANALYSIS OF GOLIMUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
    Desai, R. J.
    Rao, J.
    Biddle, A. K.
    VALUE IN HEALTH, 2012, 15 (04) : A39 - A39
  • [47] Therapeutic Options and Cost-Effectiveness for Rheumatoid Arthritis Treatment
    Drosos, Alexandros A.
    Pelechas, Eleftherios
    Kaltsonoudis, Evripidis
    Voulgari, Paraskevi V.
    CURRENT RHEUMATOLOGY REPORTS, 2020, 22 (08)
  • [48] Therapeutic Options and Cost-Effectiveness for Rheumatoid Arthritis Treatment
    Alexandros A. Drosos
    Eleftherios Pelechas
    Evripidis Kaltsonoudis
    Paraskevi V. Voulgari
    Current Rheumatology Reports, 2020, 22
  • [49] Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan
    Chen, Der-Yuan
    Hsu, Ping-Ning
    Tang, Chao-Hsiun
    Claxton, Lindsay
    Valluri, Satish
    Gerber, Robert A.
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (08) : 777 - 787
  • [50] Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
    Schlueter, Max
    Finn, Elaine
    Diaz, Silvia
    Dilla, Tatiana
    Inciarte-Mundo, Jose
    Fakhouri, Walid
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2019, 11 : 395 - 403
12345